Replimune Group
Woburn
About Replimune Group
Replimune Group develop the next generation of ‘oncolytic immunotherapies’ for the treatment of cancer. Replimune is developing novel, proprietary products intended to improve both the direct anti-tumor effects of selective virus replication and the potency of the immune response to the tumor antigens released. The Company’s Immulytic™ platform is designed to maximize systemic immune activation, in particular to tumor neoantigens, through robust viral mediated immunogenic tumor cell killing and the delivery of optimal combinations of immune activating proteins to the tumor and draining lymph nodes. The approach is expected to be highly synergistic with immune checkpoint blockade and other approaches to cancer treatment. Replimune intends to progress these therapies rapidly through clinical trials and to combine with other immuno-oncology products with complementary mechanisms of action at an early stage.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 251 – 500
- Estimated revenue: $50K – $100K
- Total funding: $1.2B
- Funding stage: IPO
- Last round: Post-IPO Equity (Nov 2024)
- Ticker: nasdaq:REPL
- Website: replimune.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/replimune-group-89705 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.